CRISPR Without the Cut: Introducing Horizon’s CRISPRi Portfolio

Time: 9:30 am
day: Day One


  • Data from the development of Horizon’s proprietary dCas9-SALL1-SDS3 repressor
  • Use of dCas9-SALL1-SDS3 mRNA and synthetic sgRNAs for potent, reversible target gene repression
  •  Use of synthetic, arrayed format CRISPRi reagents to study complex readouts not conducive to pooled studies